Welcome to the InfoSci Platform
Assessment of Anti-angiogenic Drug in Cancer Therapy

Assessment of Anti-angiogenic Drug in Cancer Therapy

Indrajit Pan
Copyright: © 2010 |Volume: 5 |Issue: 2 |Pages: 10
ISSN: 1555-3396|EISSN: 1555-340X|EISBN13: 9781609603960|DOI: 10.4018/jhisi.2010040103
Cite Article Cite Article

MLA

Pan, Indrajit. "Assessment of Anti-angiogenic Drug in Cancer Therapy." IJHISI vol.5, no.2 2010: pp.20-29. http://doi.org/10.4018/jhisi.2010040103

APA

Pan, I. (2010). Assessment of Anti-angiogenic Drug in Cancer Therapy. International Journal of Healthcare Information Systems and Informatics (IJHISI), 5(2), 20-29. http://doi.org/10.4018/jhisi.2010040103

Chicago

Pan, Indrajit. "Assessment of Anti-angiogenic Drug in Cancer Therapy," International Journal of Healthcare Information Systems and Informatics (IJHISI) 5, no.2: 20-29. http://doi.org/10.4018/jhisi.2010040103

Export Reference

Mendeley
Favorite Full-Issue Download

Abstract

It has been documented in the literature that a solid tumor survives by the generation of micro-vessels around it. This phenomenon is known as angiogenesis. Angiogenesis is governed by two factors, namely Tumor Angiogenic Factor (TAF) secreted by the tumor cells and tissue Fibronectin (FNT) concentration in the extra-cellular space. These two factors help in mobilization of endothelial cells from nearby blood vessels. At the initial phase of angiogenesis, neighboring blood vessels affect in formation of capillary sprouts. In this work, to the authors develop a clinically relevant analytical model that could act as an effective tracing system of tumor growth. The author has performed a quantitative assessment of tumor angiogenesis. This analytical method is a correlation between tumor system and vasculature system through an analytical assessment at peripheral blood circulatory of tumor milieu.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.